# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Ross Osborn reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $11 price target.
Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowers the price target from $1...
MiMedx Group (NASDAQ:MDXG) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate. The compan...
Cantor Fitzgerald has initiated coverage on MIMEDX, highlighting its strong market presence in wound care and surgical recovery...
Cantor Fitzgerald analyst Ross Osborn initiates coverage on MiMedx Group (NASDAQ:MDXG) with a Overweight rating and announce...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates MiMedx Group (NASDAQ:MDXG) with a Buy and maintains $11 pr...